Low-Dose Tocilizumab for Cytokine Release Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections such as COVID-19 and associated inflammation, particularly cytokine release syndrome, often require high doses of tocilizumab and are limited by resource constraints and the need for intensive care unit-level resources, necessitating the development of methods for effective, low-dose tocilizumab administration to manage severe inflammation and prevent clinical decompensation.
Innovation Solution
Administration of low doses of tocilizumab (200 mg or less) to patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and COVID-19, either alone or in combination with other therapeutics, to treat and prevent cytokine release syndrome, aberrant inflammatory responses, and symptoms like respiratory inflammation, guided by biomarkers like C-reactive protein and interleukin-6 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of tocilizumab are administered to treat viral infections and cytokine release syndrome, then therapeutic effectiveness is improved, but availability of therapeutic supply is reduced and resource constraints are worsened
Solution Approach 1:
The patent changes the dosage parameter of tocilizumab from conventional high doses (400-800 mg) to low doses (6.67 mg/kg or less, preferably 3.33 mg/kg or less). This parameter change maintains therapeutic effectiveness in treating cytokine release syndrome while significantly increasing the availability of therapeutic supply, allowing one vial to treat multiple patients.
Solution Approach 2:
The patent applies partial action by using a reduced dose of tocilizumab that is sufficient to treat the inflammatory response without requiring the full conventional dose. The low dose (6.67 mg/kg or less) provides partial inhibition of the IL-6 pathway, which is adequate for controlling cytokine release syndrome while preserving therapeutic resources.
2Reliability
If high doses of tocilizumab are administered to treat severe inflammation, then clinical outcomes are improved, but cost of treatment increases
Solution Approach 1:
The patent changes the dosage parameter to low doses (6.67 mg/kg or less), which reduces the cost per patient while maintaining clinical effectiveness. This parameter change directly addresses the cost issue by reducing the amount of expensive tocilizumab required per treatment.
Solution Approach 2:
The patent uses partial action with reduced dosing that is sufficient to achieve the desired clinical outcome without the excess cost of full-dose therapy. The low dose provides adequate anti-inflammatory effect at a fraction of the cost.
3Object-affected harmful factors
If conventional dosing of tocilizumab is used to treat COVID-19, then anti-inflammatory effect is achieved, but resource allocation is worsened and ICU-level resources are overwhelmed
Solution Approach 1:
The patent applies partial action by using low doses of tocilizumab that are sufficient to control inflammation in COVID-19 patients without requiring intensive care resources. This allows treatment of more patients with limited resources, improving overall resource allocation and productivity in the healthcare system.
Solution Approach 2:
The patent segments the treatment approach by dividing patients into those who require low-dose tocilizumab (most patients with COVID-19 inflammation) versus those who would require conventional high-dose therapy or ICU resources. This segmentation allows efficient use of resources by treating the majority of patients with low-dose therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Low-dose tocilizumab effectively reduces fever and C-reactive protein levels, improving clinical and biochemical indicators of hyperinflammation, thereby reducing the need for intensive care resources and optimizing the use of limited therapeutic supplies, while minimizing adverse events.
Implementation Method 1
tocilizumab (or a biosimilar thereof), a humanized anti-human interleukin-6 (IL-6) receptor antibody
Data Source
AI summary
Provided herein are methods for the treatment of viral infections and inflammation secondary to viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of low doses of tocilizumab to a subject. In particular embodiments, provided herein are pharmaceutical compositions comprising doses of 200 mg or less of tocilizumab and methods for the treatment of SARS-CoV-2 infections, COVID-19, inflammation secondary to such infections, and symptoms or other conditions arising as a result thereof.